DZDan Zhu

Dan Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dan Zhu has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Zhang

    Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery, Shanghai Chest Hospital, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    4 shared publications
  • Jianghong Guo

    The Rugao People's Hospital, Teaching Hospital of Nantong University, Rugao, Ninghai Road, Nantong, 226500, China

    3 shared publications
  • Junhao Xiong

    Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery, Shanghai Chest Hospital, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    3 shared publications
  • Kang Cheng

    Shanghai Chest Hospital

    3 shared publications
  • Shasha Zhang

    Shanghai Chest Hospital

    3 shared publications
  • Weihua Wu

    Department of Echocardiography, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

    3 shared publications

Latest Publications

  • Adeno‐Associated Virus‐Induced Humanized Hypertensive Mouse Model Validates N‐Acetylgalactosamine‐Conjugated Small Interfering RNA Targeting Angiotensinogen as a Long‐Acting Antihypertensive Therapy

    by Junhao Xiong, Shasha Zhang, Kang Cheng, Yuanzhe Sheng, Juntao Lin, Xing Liu, Tingting Liu, Xiaoling Guo, Dan Zhu, Lianpin Wu, et al.

    Background: Hypertension remains a leading cause of global morbidity and mortality, yet current therapeutic strategies lack sustained efficacy and long‐term stability. Our study aimed to construct a humanized rodent model for drugs development especially currently prevalent small interfering RNA medication. Methods: A humanized hypertensive mouse model was generated by subcutaneous injection of neonatal mice with adeno‐associated viruses encoding hAGT (human angiotensinogen) and hRENIN (human renin). Blood pressure was monitored weekly via tail‐cuff plethysmography. Expression of hAGT and hRENIN was assessed by ELISA, Western blot, and reverse transcription quantitative polymerase chain reaction. Cardiac function was evaluated by echocardiography at 4 and 6 months postinjection. Hypertension‐associated comorbidities were examined through histological analysis and ELISA. A modified N‐acetylgalactosamine‐conjugated small interfering RNA targeting human hepatic AGT (GalNAc‐siAGT) was screened and subcutaneously administered to humanized hypertensive mice, either alone or in combination with valsartan, to evaluate therapeutic efficacy. Results: The dual adeno‐associated virus‐induced humanized hypertensive model exhibited a sustained hypertension for 6 months and manifested prevalent comorbidities, including heart failure and kidney disease. This modified GalNAc‐siAGT demonstrated significant activity in knocking down hAGT both in vitro and in vivo. Only a single subcutaneous injection of GalNAc‐siAGT in humanized hypertensive mice led to a sustained reduction in blood pressure lasting for 2 months, accompanied by cardio‐ and renoprotective effects. Moreover, combining GalNAc‐siAGT with the renin‐angiotensin system blocker, valsartan, significantly enhanced therapeutic efficacy. Conclusions: Our study validated the antihypertensive therapeutic effect of GalNAc‐siAGT in a humanized hypertensive murine model while highlighting the translational potential of this model for clinical drug development.

  • Open Access

    LARP7 promotes postnatal cardiac regeneration by facilitating G2/M phase transition

    by Shasha Zhang, Kang Cheng, Junhao Xiong, Xing Liu, Juntao Lin, Huan Hu, Zilong Geng, Weimin Xu, Shizhan Xu, Ao Tan, et al.

  • Open Access

    An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure

    by Junhao Xiong, Shasha Zhang, Zilong Geng, Juntao Lin, Kang Cheng, Huan Hu, Yuze Wang, Xing Liu, Yuanzhe Sheng, Ping Yang, et al.

    BACKGROUND: Endogenous retroviruses (ERVs) occupy >8% of the human genome. Aberrant resurgence of ERVs has been implicated recently in several critical pathologies. However, the possible incidence and role of ERV resurgence in heart failure (HF), a leading cause of global morbidity and mortality, remain unexplored. METHODS: We established a total RNA sequencing analyzing pipeline to assess the ERV occurrence in human and murine HF models. We generated 2 myocardium-specific mouse lines by crossing Myh6 -MerCreMer with TRIM28 f/f and SETDB1 f/f mice to identify the molecular regulators of ERV resurgence and the downstream pathways in the heart. We evaluated ERV expression by total RNA sequencing, reverse transcription-quantitative polymerase chain reaction and RNA fluorescence in situ hybridization. We restrained ERV activation by overexpressing TRIM28 (tripartite motif–containing 28) using adeno-associated virus serotype 9. The therapeutic potential of the ERV-mediated inflammatory pathway was tested in a myocardial ischemia/reperfusion model. RESULTS: ERVs, particularly class I ERVs, were prominently activated in multiple cross-species models of HF. Depletion of TRIM28, an epigenetic repressor, attenuated the epigenetic surveillance of trimethylation at lysine 9 of histone H3 and N 6 -methyladenosine, leading to the activation of ERVs in the failing heart. This ERV activation stimulated the antiviral innate immune pathways of TLR7/9 (Toll-like receptor 7/9) and NF-κB and lead to myocarditis and acute HF. Furthermore, restraining ERV activation and ERV-mediated innate immune responses by either adeno-associated virus serotype 9–mediated TRIM28 expression or a small-molecule TLR7/9 inhibitor improved heart function and alleviated HF in an ischemia/reperfusion model. CONCLUSIONS: ERV resurgence is a specific molecular trait of HF, driven by TRIM28 depletion in cardiomyocytes. ERV resurgence activates the innate immune TLR7/9–NF-κB pathway and induces myocarditis and HF. Inception of ERVs and the ERV-mediated immune pathway confers cardiac protection. These results identify TRIM28–ERV–TLR7/9–NF-κB as a target for therapeutic management of myocarditis and HF.


  • Open Access

    Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice

    by Shuo Wu, Ping Yang, Zilong Geng, Yige Li, Zhizhao Guo, Yingmei Lou, Shasha Zhang, Junhao Xiong, Huan Hu, Xiaoling Guo, et al.


  • Open Access

    Single-cell transcriptomics reveals cellular heterogeneity and macrophage-to-mesenchymal transition in bicuspid calcific aortic valve disease

    by Tao Lyu, Yang Liu, Binglin Li, Ran Xu, Jianghong Guo, Dan Zhu

    Background: Bicuspid aortic valve (BAV) is the most prevalent congenital valvular heart defect, and around 50% of severe isolated calcific aortic valve disease (CAVD) cases are associated with BAV. Although previous studies have demonstrated the cellular heterogeneity of aortic valves, the cellular composition of specific BAV at the single-cell level remains unclear. Methods: Four BAV specimens from aortic valve stenosis patients were collected to conduct single-cell RNA sequencing (scRNA-seq). In vitro experiments were performed to further validate some phenotypes. Results: The heterogeneity of stromal cells and immune cells were revealed based on comprehensive analysis. We identified twelve subclusters of VICs, four subclusters of ECs, six subclusters of lymphocytes, six subclusters of monocytic cells and one cluster of mast cells. Based on the detailed cell atlas, we constructed a cellular interaction network. Several novel cell types were identified, and we provided evidence for established mechanisms on valvular calcification. Furthermore, when exploring the monocytic lineage, a special population, macrophage derived stromal cells (MDSC), was revealed to be originated from MRC1+ (CD206) macrophages (Macrophage-to-Mesenchymal transition, MMT). FOXC1 and PI3K-AKT pathway were identified as potential regulators of MMT through scRNA analysis and in vitro experiments. Conclusions: With an unbiased scRNA-seq approach, we identified a full spectrum of cell populations and a cellular interaction network in stenotic BAVs, which may provide insights for further research on CAVD. Notably, the exploration on mechanism of MMT might provide potential therapeutic targets for bicuspid CAVD.


  • Open Access

    Iron promotes Slc7a11-deficient valvular interstitial cell osteogenic differentiation: A possible mechanism by which ferroptosis participates in intraleaflet hemorrhage-induced calcification

    by Ran Xu, Dan Zhu, Jianghong Guo, Ying Huang

    Background Calcific aortic valve disease (CAVD) is the most frequent pathogeny of aortic valve replacement in developed countries. Iron deposits are found in the intraleaflet hemorrhage (IH) areas of calcific aortic valves. Ferroptosis is a form of regulated cell death that involves metabolic dysfunction resulting from iron overload-dependent excessive lipid peroxidation. In this research, we attempted to clarify the role of ferroptosis in CAVD. Methods The level of ferroptosis in tissue and valvular interstitial cells (VICs) was assessed by the contents of 4-HNE, NADPH, ROS, and GSH, lipid peroxidation and mitochondrial morphology. The levels of calcification, iron accumulation and Slc7a11 expression in surgical aortic valve specimens were detected by Alizarin red or Von Kossa, Perl’s blue and immunohistochemical staining. The osteogenic differentiation of VICs was assessed by PCR and western blot analyses. Furthermore, RNA sequencing was used to detect potential differentially expressed genes between normal and osteogenic medium-treated (OM-treated) VICs. Results Our experiments demonstrated that ferroptosis occurred in the IH areas of calcific aortic valves. We also found that Slc7a11 was expressed at low levels in OM-treated VICs and IH areas. Finally, we demonstrated that iron promoted Slc7a11-deficient VICs osteogenic differentiation by aggravating ferroptosis in vitro. Conclusion In conclusion, iron promotes Slc7a11-deficient VIC osteogenic differentiation by aggravating ferroptosis in vitro, thereby accelerating the progression of aortic valve calcification. Statement Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), Society, or publisher, and the Editor(s), Society, and publisher disclaim any responsibility or liability for such material. Brief Summary In this work, two novel notions have been proposed. First, we reported that ferroptosis participated in the progression of CAVD. Second, this is the first cytology experiment of valvular interstitial cells (VICs) to clarify the mechanism by which intraleaflet hemorrhage aggravates calve calcification. This research provides new ideas and targets for alleviating the progression of CAVD, especially in patients who have calcified aortic valves without severe stenosis.


  • Open Access

    Histological chorioamnionitis is associated with an increased risk of wheezing in preterm children less than 34 gestational weeks

    by Xiaoli Wang, Haiyuan Li, Qianqian Zhang, Qianwen Shen, Dan Zhu, Hong Li, Zheng Tang, Jiuru Zhao, Zhiwei Liu

    Chorioamnionitis is associated with various neonatal short- and long-term morbidities. The effect of chorioamnionitis on premature children’s outcomes remains controversial. The aim of this study is to investigate the relationship between histological chorioamnionitis (HCA) and physiological development, wheezing, and atopic diseases in preterm children. Singleton, preterm children (< 34 weeks), whose mother underwent pathological placental examinations, were retrospectively enrolled and the outcomes were assessed at 24–40 months during follow-up. Wheezing and atopic diseases including eczema, food allergies, and allergic rhinitis were screened by a questionnaire along with medical diagnosis. Anthropometric indexes and blood pressure were measured. Cognitive and behavioural developments were assessed by the Gesell Development and Diagnosis Scale. Blood IgE and routine examination were analyzed with venous blood and serum metabolomic profiling was assessed via liquid chromatography-mass spectrometry (LC-MS). A multivariate logistic regression model was used to estimate the association between HCA and the current outcomes. Among the 115 enrolled children, 47 were exposed to HCA. The incidence of wheezing was significantly higher in children exposed to HCA, as 38.30% of children who were exposed to HCA and 16.18% of children who were not had been diagnosed with wheezing. After adjusting for related confounders in the multivariate logistic regression model, there remained a 2.72-fold increased risk of wheezing in children with HCA (adjusted odds ratio, aOR, 2.72; 95% confidence interval, 1.02–7.23). Moreover, 163 differential metabolites, such as butanoic acid, annotemoyin 1 and charine, were identified in the HCA exposed children’s serum. Enrichment analysis revealed that these compounds participated in diverse key metabolomic pathways relating to physical and neuro- developments, including glycerophospholipid, alpha-linolenic acid and choline metabolisms. There were no significant differences in atopic diseases, serum IgE, eosinophils’ level, anthropometric indexes, blood pressure, or cognitive or behavioural developments between the two groups. HCA exposure is associated with an increased risk of wheezing in preterm children less than 34 gestational weeks.